ALPL and hypophosphatasia: ERT using asfotase alfa was shown to be very effective at correcting skeletal and dentoalveolar defects in Alpl−/− mice, with these translational studies leading to its approval in 2015 for treatment of patients with perinatal/infantile‐ and juvenile‐onset HPP, except in Japan, where asfotase alfa is approved for all ages.(25) However, asfotase alfa ERT requires multiple injections per week, is associated with injection site reactions, and is expensive,(27, 28) prompting additional preclinical studies of alternative strategies for HPP treatment.